Study Shows Entresto (Sacubitril / valsartan) Improves Physical, Social Activity in Heart Failure Patients - Novartis
![These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO. ENTRESTO® (sacubitril and valsartan) tablets, for oral use Initial U.S. Approval: These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO. ENTRESTO® (sacubitril and valsartan) tablets, for oral use Initial U.S. Approval:](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=ENTRESTO-08.jpg&id=622573)
These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO. ENTRESTO® (sacubitril and valsartan) tablets, for oral use Initial U.S. Approval:
![New analyses show Novartis' EntrestoTM reduced cardiovascular death or hospitalization forheart failure, consistently benefitting patients with reduced ejection fractionregardless of prior heart failure hospital admissions or background therapy | Novartis New analyses show Novartis' EntrestoTM reduced cardiovascular death or hospitalization forheart failure, consistently benefitting patients with reduced ejection fractionregardless of prior heart failure hospital admissions or background therapy | Novartis](https://novartis.gcs-web.com/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2017/03/31/5-41-45/2138Photo1.png?itok=3HOFVrIh)